Women exposed to single-dose nevirapine in successive pregnancies: Effectiveness and nonnucleoside reverse transcriptase inhibitor resistance

AIDS

Volumn 23, Issue 7, 2009, Pages 809-816

  Martinson, Neil A ^a,b,e   Morris, Lynn ^c   Johnson, Jeffrey ^d   Gray, Glenda E ^b   Pillay, Visva ^c   Ledwaba, Johanna ^c   Dhlamini, Puleng ^b   Cohen, Sarah ^c   Puren, Adrian ^c   Steyn, Jan ^b   Heneine, Walid ^d   McIntyre, James A ^b  

^a SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e Perinatal HIV Research Unit   (South Africa)

Author keywords

Allele specific pcr; Clade c; Drug resistance; Mother to child transmission; Single dose nevirapine; South africa

Indexed keywords

CD4 ANTIGEN; NEVIRAPINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ALLELE; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; MAJOR CLINICAL STUDY; MATERNAL AGE; MULTIPARA; NEWBORN INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERIUM; RETREATMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; UNINDEXED SEQUENCE; VERTICAL TRANSMISSION; VIRUS LOAD; ADULT; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG ADMINISTRATION; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MULTICENTER STUDY; NEWBORN; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATION; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; NEVIRAPINE; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 67649658009     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328323ad49     Document Type: Article

References (40)

1. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802.
2. JacksonJB, Musoke P, FlemingT, Guay LA, Bagenda D, Allen M, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003;362:859-868.
3. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang- Huong N, Koetsawang S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. New Engl J Med 2004;351:217-228.
4. Dabis F, Bequet L, Ekouevi DK, Viho I, Rouet F, Horo A, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 2005; 19:309-318.
5. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. JInfect Dis 2005; 192:30-36.
6. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-1957.
7. Martinson N, Morris L, Gray G, Moodley D, Lupondwana P, Chezzi C, et al. HIV resistance and transmission following single dose nevirapine in a PMTCT cohort [abstract 38]. 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, CA.
8. Morris L, Martinson N, Pillay C, Moodley D, Chezzi C, Lupond- wana P, et al. Persistence of nevirapine resistance mutations 6 months following single dose nevirapine [abstract ThOrB1353]. XV International AIDS Conference; 2004; Bangkok, Thailand.
9. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 2006; 20:995-1002.
10. Johnson JA, Li JF, Morris L, Martinson N, Gray G, McIntyre J, Heneine W. Emergence of drug-resistant HIV-1 after intrapar- tum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005;192:16-23.
11. Flys TS, Donnell D, Mwatha A, Nakabiito C, Musoke P, Mmiro F, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007;195:711-715.
12. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356: 135-147.
13. Jourdain G, Ngo-Giang-Huong N, LeCoeurS, Bowonwatanu- wong C, Kantipong P, Leechanachai P, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. NEnglJMed 2004;351:229-240.
14. Gould WT, Brown MS. A fertility transition in Sub-Saharan Africa? Int J Popul Geogr 1996;2:1-22.
15. Measure DHS. Demographic and Health Surveys. http:// www.measuredhs.com. 2006. [Accessed 04 June 2008].
16. Stanwood NL, Cohn SE, Heiser JR, Pugliese M. Contraception and fertility plans in a cohort of HIV-positive women in care. Contraception 2007;75:294-298.
17. Sedgh G, Larsen U, Spiegelman D, Msamanga G, Fawzi WW. HIV-1 infection and fertility in Dar es Salaam, Tanzania. Afr J Reprod Health 2006;10:41-52.
18. Lewis JJ, Ronsmans C, Ezeh A, Gregson S. The population impact of HIV on fertility in sub-Saharan Africa. AIDS 2004; 18 (Suppl 2):S35-S43.
19. Fabiani M, Nattabi B, Ayella EO, Ogwang M, Declich S. Differences in fertility by HIV serostatus and adjusted HIV prevalence data from an antenatal clinic in northern Uganda. Trop Med Int Health 2006;11:182- 187.
20. Von Gordon J. World AIDS Day 2005 - Boehringer Ingelheim is committed to its fight against AIDS. http://www.boehringer- ingelheim.com/corporate/asp/news/ ndetail.asp?ID=3434. 2005. [Accessed 04 June 2008].
21. Martinson NA, Ekouevi DK, Dabis F, Morris L, Lupodwana P, Tonwe-Gold B, et al. Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2007;45:206-209.
22. Nattrass N. South Africa's 'Rollout' of highly active antiretroviral therapy: a critical assessment. J Acquir Immune Defic Syndr 2006;43:618-623.
23. Martinson NA, Morris L, Gray G, Moodley D, Pillay V, Cohen S, et al. Selection and persistence of viral resistance in HIV- infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007;44:148-153.
24. van der Tweel I, van Noord PA, Kaaks R. Application of a sequential t-test in a cohort nested case-control study with multiple controls per case. J Clin Epidemiol 1993;46:253-259.
25. Pasternack BS, Shore RE. Sample sizes for individually matched case-control studies: a group sequential approach. Am J Epidemiol 1982;115:778-784.
26. McConnell MS, Bakaki P, Eure C, Mubiru M, Bagenda D, Downing R, etal. Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies, Uganda. J Acquir Immune Defic Syndr2007; 46:291-296.
27. Taha TE, Kumwenda NI, Hoover DR, Fiscus SA, Kafulafula G, Nkhoma C, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004;292:202-209.
28. Sherman GG, Jones SA, Coovadia AH, Urban MF, Bolton KD. PMTCT from research to reality - results from a routine service. S Afr Med J 2004;94:289-292.
29. Ayouba A, Tene G, Cunin P, Foupouapouognigni Y, Menu E, Kfutwah A, et al. Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaounde, Cameroon. J Acquir Immune Defic Syndr 2003;34:274-280.
30. Colvin M, Chopra M, Doherty T, Jackson D, Levin J, Willumsen J, et al. Operational effectiveness of single-dose nevirapine in preventing mother-to-child transmission of HIV. Bull World Health Organ 2007;85:466-473.
31. Mandelbrot L, LeChenadecJ, Berrebi A, Bongain A, BeniflaJL, Delfraissy JF, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998;280:55-60.
32. Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM. Randomized trial testing the effect of vitamin A supplementation on pregnancy outcomes and early mother-to-child HIV-1 transmission in Durban, South Africa. South African Vitamin A Study Group. AIDS 1999;13:1517-1524.
33. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002;359:1178-1 186.
34. Lallemant M, Le Coeur S, Samba L, Cheynier D, M'Pele P, NzingoulaS, Essex M. Mother-to-child transmission of HIV-1 in Congo, Central Africa. Congolese Research Group on Mother- to-Child Transmission of HIV. AIDS 1994;8:1451-1456.
35. Albrecht S, Semrau K, Kasonde P, Sinkala M, Kankasa C, Vwalika C, et al. Predictors of nonadherence to single-dose nevirapine therapy for the prevention of mother-to-child HIV transmission. JAcquirImmune Defic Syndr 2006; 41:114-118.
36. Rankin WW, Brennan S, Schell E, Laviwa J, Rankin SH. Thestigma of being HIV-positive in Africa. PLoS Med 2005;2:e247.
37. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
38. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517.
39. Wind-Rotolo M, Durand C, Cranmer L, Reid A, Siliciano J, Doherty M, etal. Identification of nevirapine-resistant HIV-1 in the latent reservoir following single-dose nevirapine [abstract 634]. 15th Conference on Retroviruses and Opportunistic Infections; 3 -6 February 2008; Boston, MA.
40. Eshleman SH, Guay LA, Mwatha A, Cunningham SP, Brown ER, Musoke P, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose NVP prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses 2004;20:595-599.